Plasminogen Activator Inhibitor 1 (PAI-1) and Haematologic Parameters in HIV- Positive Patients on Protease Inhibitor-Based HAART Regimen: A Case-Control Study

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2022 Nov 22

PMID 36411985

Authors

Chimeziem Christopher

Benedict Nwogoh

Kingsley Akaba

Hilary Igwilo

Roger Abang

Affiliations

Soon will be listed here.

Abstract

Human immunodeficiency virus (HIV) infection is associated with an increased risk of hypercoagulability and treatment with antiretroviral agents especially protease inhibitors has also been reported to contribute to this risk. Altered fibrinolytic activity is reported as a mechanism of increased thrombotic risk in HIV patients on therapy. However, this has not been investigated in our environment. To evaluate and compare PAI-1 levels as a marker of thrombotic risk in HIV-infected persons on PI-based HAART regimen with those on non-PI-based therapy and to correlate PAI-1 with haematological parameters. This was a comparative cross-sectional study conducted at the University of Calabar Teaching Hospital (UCTH), Calabar, Cross River State. A total of 125 subjects including 45 HIV-positive patients on PI-based HAART regimen, 42 HIV-positive patients on non-PI-based HAART regimen and 38 Controls. The controls include 18 HIV-positive therapy naïve patients and 20 HIV-negative controls. PAI 1 and blood counts were estimated using standard methods. Data were analyzed using the IBM version of the statistical package for social sciences (SPSS) version 22. Statistical significance was set at 0.05. The median PAI-1 level was significantly increased in patients on PI-based HAART regimen (p = 0.004). The blood counts did not differ significantly between patients on PI and non-PI-based HAART regimens (p > 0.05). There were no significant correlations between PAI-1 levels and blood counts (p > 0.05). PAI-1 level is elevated in HIV patients on PI-based HAART regimen. However, the association with thrombotic events could not be established in the study.

References

Stafford K, Odafe S, Lo J, Ibrahim R, Ehoche A, Niyang M . Evaluation of the clinical outcomes of the Test and Treat strategy to implement Treat All in Nigeria: Results from the Nigeria Multi-Center ART Study. PLoS One. 2019; 14(7):e0218555. PMC: 6619660. DOI: 10.1371/journal.pone.0218555. View

Saber A, Aboolian A, LaRaja R, Baron H, Hanna K . HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg. 2001; 67(7):645-7. View

Fultz S, McGinnis K, Skanderson M, Ragni M, Justice A . Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med. 2004; 116(6):420-3. DOI: 10.1016/j.amjmed.2003.10.011. View

Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E . Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 29(5):441-9. DOI: 10.1097/00042560-200204150-00003. View

Sousa A, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino R . CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002; 169(6):3400-6. DOI: 10.4049/jimmunol.169.6.3400. View

Yasar Yildiz S, Kuru P, Toksoy Oner E, Agirbasli M . Functional stability of plasminogen activator inhibitor-1. ScientificWorldJournal. 2014; 2014:858293. PMC: 4214104. DOI: 10.1155/2014/858293. View

de Larranaga G, Bocassi A, Puga L, Alonso B, Benetucci J . Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res. 2003; 110(2-3):93-8. DOI: 10.1016/s0049-3848(03)00291-3. View

Okoye A, Picker L . CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013; 254(1):54-64. PMC: 3729334. DOI: 10.1111/imr.12066. View

Pirs M, Jug B, Erzen B, Sabovic M, Karner P, Poljak M . Relationship between markers of endothelial dysfunction and inflammation and subclinical atherosclerosis in HIV-infected male patients below 55 years of age. Acta Dermatovenerol Alp Pannonica Adriat. 2014; 23(3):49-52. DOI: 10.15570/actaapa.2014.12. View

10.

Wirunsawanya K, Belyea L, Shikuma C, Watanabe R, Kohorn L, Shiramizu B . Plasminogen Activator Inhibitor-1 Predicts Negative Alterations in Whole-Body Insulin Sensitivity in Chronic HIV Infection. AIDS Res Hum Retroviruses. 2017; 33(7):723-727. PMC: 5749045. DOI: 10.1089/AID.2016.0292. View

11.

Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R, Montiel-Manzano G, Trevino-Perez S, Santoscoy-Gomez M . Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost. 2004; 10(1):19-25. DOI: 10.1177/107602960401000104. View

12.

Sullivan P, Dworkin M, Jones J, Hooper W . Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS. 2000; 14(3):321-4. DOI: 10.1097/00002030-200002180-00015. View

13.

Friis-Moller N, Sabin C, Weber R, Monforte A, El-Sadr W, Reiss P . Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349(21):1993-2003. DOI: 10.1056/NEJMoa030218. View

14.

Bibas M, Biava G, Antinori A . HIV-Associated Venous Thromboembolism. Mediterr J Hematol Infect Dis. 2011; 3(1):e2011030. PMC: 3152452. DOI: 10.4084/MJHID.2011.030. View

15.

Young E, Considine R, Sattler F, Deeg M, Buchanan T, Degawa-Yamauchi M . Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. Cardiovasc Toxicol. 2004; 4(2):179-86. DOI: 10.1385/ct:4:2:179. View

16.

Crum-Cianflone N, Weekes J, Bavaro M . Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS. 2008; 22(10):771-8. PMC: 2753452. DOI: 10.1089/apc.2008.0010. View

17.

Gibellini D, Borderi M, Clo A, Morini S, Miserocchi A, Bon I . Antiretroviral molecules and cardiovascular diseases. New Microbiol. 2012; 35(4):359-75. View

18.

Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F . Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis. 2011; 11:40. PMC: 3042932. DOI: 10.1186/1471-2334-11-40. View

19.

Knudsen A, Katzenstein T, Benfield T, Jorgensen N, Kronborg G, Gerstoft J . Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. AIDS. 2014; 28(8):1171-9. DOI: 10.1097/QAD.0000000000000247. View

20.

Rufu A, Chitimbire V, Nzou C, Timire C, Owiti P, Harries A . Implementation of the 'Test and Treat' policy for newly diagnosed people living with HIV in Zimbabwe in 2017. Public Health Action. 2018; 8(3):145-150. PMC: 6147065. DOI: 10.5588/pha.18.0030. View